BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.020
+0.010 (0.50%)
Jan 12, 2026, 4:00 PM EST - Market closed
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -66.54% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover BioXcel Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26.67, which forecasts a 1,220.30% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $66.
Price Target: $26.67 (+1,220.30%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 15, 2025.
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +395.05% | Sep 15, 2025 |
| Mizuho | Mizuho | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +98.02% | Sep 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +395.05% | Aug 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +395.05% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $10 | Strong Buy | Maintains | $8 → $10 | +395.05% | Aug 15, 2025 |
Financial Forecast
Revenue This Year
585.07K
from 2.27M
Decreased by -74.18%
Revenue Next Year
3.17M
from 585.07K
Increased by 441.98%
EPS This Year
-6.58
from -23.51
EPS Next Year
-3.19
from -6.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 669,900 | 6.4M | ||||
| Avg | 585,072 | 3.2M | ||||
| Low | 490,000 | 392,000 |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -70.4% | 991.1% | ||||
| Avg | -74.2% | 442.0% | ||||
| Low | -78.4% | -33.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.97 | -2.17 | ||||
| Avg | -6.58 | -3.19 | ||||
| Low | -7.38 | -4.16 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.